| Mark Gladwin, | |
|
Vmb Nhlbi Nih 10 Center Dr, Building 10, Room 55140, Bethesda, MD 20892-0001 | |
| (301) 435-2310 | |
| Not Available |
| Full Name | Mark Gladwin |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 33 Years |
| Location | Vmb Nhlbi Nih 10 Center Dr, Bethesda, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790997666 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | D0052428 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Maryland Medical Center | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Maryland Physicians P.a. | 2769394808 | 313 |
News Archive
Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer (NSCLC).
Premiums for plans sold through the online marketplaces are lower, across the board, than the average premiums for the majority of Americans with work-based coverage, according to a report by PwC's Health Research Institute. Meanwhile, California lawmakers criticize the hiring of people with criminal records to be insurance counselors and labor leaders continue to complain the law will undermine coverage for their members.
The Pulmonary Fibrosis Foundation (PFF) announced today that registration is now open for the IPF Summit 2011: From Bench to Bedside. The conference will feature an innovative two-day continuing medical education (CME) program for physicians, researchers, and other health care professionals. Additionally there will be a separate one-day patient, family member, and caregiver program to address the growing educational needs of the idiopathic pulmonary fibrosis (IPF) community.
Nabi Biopharmaceuticals announced that it has initiated the second of two pivotal Phase III clinical trials for NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary vaccine to treat nicotine addiction and prevent smoking relapse. The FDA has agreed with Nabi on the study design, protocol and end points through a Special Protocol Assessment (SPA). The SPA forms a basic foundation to support approval of a New Drug Application. The Company also received scientific advice from the European Medicines Agency (EMEA) that confirms and supports the trial protocol.
› Verified 1 days ago
| Entity Name | University Of Maryland Physicians P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689623175 PECOS PAC ID: 2769394808 Enrollment ID: O20031105000792 |
News Archive
Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer (NSCLC).
Premiums for plans sold through the online marketplaces are lower, across the board, than the average premiums for the majority of Americans with work-based coverage, according to a report by PwC's Health Research Institute. Meanwhile, California lawmakers criticize the hiring of people with criminal records to be insurance counselors and labor leaders continue to complain the law will undermine coverage for their members.
The Pulmonary Fibrosis Foundation (PFF) announced today that registration is now open for the IPF Summit 2011: From Bench to Bedside. The conference will feature an innovative two-day continuing medical education (CME) program for physicians, researchers, and other health care professionals. Additionally there will be a separate one-day patient, family member, and caregiver program to address the growing educational needs of the idiopathic pulmonary fibrosis (IPF) community.
Nabi Biopharmaceuticals announced that it has initiated the second of two pivotal Phase III clinical trials for NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary vaccine to treat nicotine addiction and prevent smoking relapse. The FDA has agreed with Nabi on the study design, protocol and end points through a Special Protocol Assessment (SPA). The SPA forms a basic foundation to support approval of a New Drug Application. The Company also received scientific advice from the European Medicines Agency (EMEA) that confirms and supports the trial protocol.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Gladwin, Vmb Nhlbi Nih 10 Center Dr, Building 10, Room 55140, Bethesda, MD 20892-0001 Ph: () - | Mark Gladwin, Vmb Nhlbi Nih 10 Center Dr, Building 10, Room 55140, Bethesda, MD 20892-0001 Ph: (301) 435-2310 |
News Archive
Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer (NSCLC).
Premiums for plans sold through the online marketplaces are lower, across the board, than the average premiums for the majority of Americans with work-based coverage, according to a report by PwC's Health Research Institute. Meanwhile, California lawmakers criticize the hiring of people with criminal records to be insurance counselors and labor leaders continue to complain the law will undermine coverage for their members.
The Pulmonary Fibrosis Foundation (PFF) announced today that registration is now open for the IPF Summit 2011: From Bench to Bedside. The conference will feature an innovative two-day continuing medical education (CME) program for physicians, researchers, and other health care professionals. Additionally there will be a separate one-day patient, family member, and caregiver program to address the growing educational needs of the idiopathic pulmonary fibrosis (IPF) community.
Nabi Biopharmaceuticals announced that it has initiated the second of two pivotal Phase III clinical trials for NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary vaccine to treat nicotine addiction and prevent smoking relapse. The FDA has agreed with Nabi on the study design, protocol and end points through a Special Protocol Assessment (SPA). The SPA forms a basic foundation to support approval of a New Drug Application. The Company also received scientific advice from the European Medicines Agency (EMEA) that confirms and supports the trial protocol.
› Verified 1 days ago
Ardalan Enkeshafi, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 6410 Rockledge Dr Ste 304, Bethesda, MD 20817 Phone: 443-602-6207 | |
Dr. Tara Palmore, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Center Dr, Msc 1888, Bethesda, MD 20892 Phone: 301-496-4000 | |
Dr. Cornelia Diana Cudrici, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Center Drive Bld 10 Rm 6n216a, Bethesda, MD 20892 Phone: 301-443-5519 | |
Shanthi Murgesh Nadar, Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 8600 Old Georgetown Road, Bethesda, MD 20814 Phone: 301-896-3100 | |
Dr. Nicole Jeanine Gormley, M.D. Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 10 Center Dr, Bldg 10, Rm 2c145, Bethesda, MD 20892 Phone: 301-496-9320 | |
Dr. Harshkumar Patel, MBBS Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 10 Center Dr, Bethesda, MD 20892 Phone: 301-496-9320 Fax: 301-402-1213 | |
Dr. Tung N Dao, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 6410 Rockledge Dr, Ste 200, Bethesda, MD 20817 Phone: 301-897-5301 Fax: 301-564-4289 |